A new research has established the benefit of commencing of asymptomatic and mild-symptom COVID-19 patients in an outpatient setting with hydroxychloroquine and azithromycin.
This, the research found, could prevent a deterioration resulting in a trip to the Intensive Care Unit (ICU).
Two Chinese researchers, Liu Wenzhong and Li Hualan had published the result of the study on March 27 as the world grapples with the effect of the virus, which has killed more than 70,000 as of April 8.
American entrepreneur and social media consultant, Mike Coudrey explained the key findings of the study, which was conducted to enable doctors better understand the deadly virus, thus:
NEW RESEARCH: COVID-19 is causing prolonged & progressive hypoxia (starving your body of oxygen) by binding to the heme groups in hemoglobin in your red blood cells.
Patients are progressively desaturating (losing o2 in their blood), & as a result, it’s leading to organ failures
COVID-19 glycoproteins bond to the heme groups, and in doing so the oxidative iron ion is “disassociated” (released) from red blood cells.
Without the iron ion, hemoglobin can no longer bind to oxygen, rendering the red blood cells useless.
It is very likely that this is more the case, rather than developing a form of ARDS or pneumonia.
Many doctors are starting to believe that they are operating under a false notion of pneumonia, & possibly treating the wrong symptoms on a systematic basis throughout the country.
Ventilators may not be treating the root cause, as many of the patient’s lungs aren’t ‘tiring out’, they’re pumping just fine.
It is instead that the affected hemoglobin have been stripped of their ability to carry oxygen, resulting in hypoxia.
The body compensates for this lack of o2 carrying capacity by having your kidneys release hormones like erythropoietin, which tell your bone marrow factories to ramp up production on new red blood cells with freshly made and fully functioning hemoglobin.
This is the reason you find elevated hemoglobin and decreased blood oxygen saturation as one of the 3 primary indicators of poor prognosis for a particular patient.
If the patient’s immune system doesn’t fight off the virus in time before their blood oxygen saturation drops too low, ventilator or no ventilator, organs start shutting down.
The only way to try to keep them going is by delivering oxygen or a transfusion of red blood cells.
This is why it is absolutely crucial to treat patients in an outpatient setting with hydroxychloroquine and azithromycin, before they deteriorate and have to go to the ICU.
Hydroxychloroquine is also used for malaria, a pathogen that also interferes with the red blood cells. Malaria uses host hemoglobin as its food source.
HCQ interferes with COVID-19 surface spike proteins and prevents them from dislodging the hemoglobin in the red blood cells.
HCQ also effects some aspects of cellular PH, preventing viral replication and entry.
In conclusion, Physicians may need to re-evaluate treatment options and their basis-of-understanding for COVID-19, in light of its newly realized ability to induce hypoxemia in the patient.
Watch New York-based doctor, Dr. Cameron Kyle-Sidell explain the dilemma in treating this novel disease:
https://m.youtube.com/watch?feature=youtu.be&v=g3ka8lo_fZ8#menu
Read Also: Smoking Increases the risk of Contracting COVID-19